Molecular Partners Ag (MOLN) Total Current Liabilities (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Total Current Liabilities of $11236.4 for Q1 2026, up 12.69% year-over-year from $9971.3 in Q1 2025, and down 18.56% quarter-over-quarter from $13796.6 in Q4 2025.
Molecular Partners Ag (MOLN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Total Current Liabilities for 7 consecutive years, with $11236.4 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 12.69% year-over-year to $11236.4; the TTM figure through Mar 2026 stood at $11236.4 (up 12.69% YoY), while the FY2025 annual figure was $13796.6, down 99.89% from the prior year.
- Total Current Liabilities retreated to $11236.4 in Q1 2026 per MOLN's latest filing, from $13796.6 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $24.2 million in Q2 2022 and bottomed at $9971.3 in Q1 2025.
- Historically, Total Current Liabilities has averaged $5.9 million across 5 years, with a median of $16626.1 in 2023.
- On a YoY basis, Total Current Liabilities climbed as much as 21.87% in 2025 and fell as far as 99.89% in 2025.
- Molecular Partners Ag's Total Current Liabilities stood at $17.9 million in 2022, then dropped by 9.24% to $16.3 million in 2023, then declined by 24.25% to $12.3 million in 2024, then tumbled by 99.89% to $13796.6 in 2025, then dropped by 18.56% to $11236.4 in 2026.
- Business Quant data shows MOLN's Total Current Liabilities at $11236.4 in Q1 2026, $13796.6 in Q4 2025, and $14678.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 11,236.36 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,236.36 |
| Dec 31, 2025 | 13,796.65 |
| Sep 30, 2025 | 14,678.79 |
| Jun 30, 2025 | 15,578.16 |
| Mar 31, 2025 | 9,971.33 |
| Dec 31, 2024 | 12.31 Mn |
| Sep 30, 2024 | 12,044.15 |
| Jun 30, 2024 | 12.56 Mn |
| Mar 31, 2024 | 14,066.69 |
| Dec 31, 2023 | 16.25 Mn |
| Sep 30, 2023 | 16,460.37 |
| Jun 30, 2023 | 17.43 Mn |
| Mar 31, 2023 | 16,626.12 |
| Dec 31, 2022 | 17.91 Mn |
| Sep 30, 2022 | 19,721.31 |
| Jun 30, 2022 | 24.21 Mn |
| Mar 31, 2022 | 32,952.02 |
| Dec 31, 2021 | 50.83 Mn |
| Sep 30, 2021 | 43,221.00 |
| Dec 31, 2020 | 63.79 Mn |